Last reviewed · How we verify
NCT04564573
Antidepressant Treatments and Cognitive Function of Bipolar Patients
trial in Bipolar Disorder in 124 participants. Status unknown.
1 July 2022
Quick facts
| Lead sponsor | Tianjin Anding Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 124 |
| Start date | 1 July 2020 |
| Primary completion | 1 July 2022 |
| Estimated completion | 30 October 2022 |
| Sites | 1 location across China |
Conditions studied
- Bipolar Disorder — all drugs for Bipolar Disorder →
- Cognition — all drugs for Cognition →
Sponsor
Tianjin Anding Hospital
Who can join
Adults 18 to 50, any sex, with Bipolar Disorder or Cognition. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with bipolar disorder (BD) have a wide range of neurocognitive dysfunction, which lead to impaired psychosocial function and reduced quality of life. Therefore, improving neurocognitive function has become an important goal of BD treatment. Aiming at this, some clinical studies have been performed but failed to illustrate significant positive efficacies of pharmacological therapy or non-pharmacological therapy, which could attribute in part to insufficient understanding on the risk factors that affect the neurocognitive function of BD patients. Delayed diagnosis of BD is so common that a lot of patients receive long-term antidepressant treatment before of diagnosis of unipolar depression. There is controversy about whether antidepressant treatment in early stage would affect the neurocognitive function of BD patients. In view of the high prevalence of delayed diagnosis and the use of antidepressants, it is of great scientific significance and clinical value to clarify this matter and other factors that may potentially affect the neurocognitive function of BD patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Study on exosomes for identifying bipolar disorder in early stage: A cross-sectional and validation study protocol.
Wu Y, Li Y, An X, Li J, et al · · 2024 · cited 3× · PMID 38641892 · DOI 10.1002/brb3.3494 -
The effect of systemic antidepressant treatments in early stage on neurocognitive function of euthymic bipolar patients initiated with a depressive onset: An observational, cross-sectional, single-blind study protocol.
Yang H, Liu Y, Yang C, Lin X. · · 2021 · cited 2× · PMID 34520638 · DOI 10.1002/brb3.2360
Verify or expand the search:
- PubMed search for NCT04564573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bipolar Disorder
Currently open trials in the same condition.
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT06911931 — Visual Perception in Schizophrenia · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07479758 — Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Out · recruiting
- NCT07140913 — A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur · Phase 3 · recruiting
Other Tianjin Anding Hospital trials
Trials by the same sponsor.
- NCT07393464 — PQQ for Cognitive and Negative Symptoms · NA · not yet recruiting
- NCT07523490 — Investigation on Suicide Risk Factors of Patients With Mood Disorders · recruiting
- NCT06812923 — TACS on High-inflammatory and Refractory Depression · NA · recruiting
- NCT07162467 — Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia. · enrolling by invitation
- NCT07359209 — Berberine Improving Cognitive Impairments in Schizophrenia · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04564573 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Anding Hospital
- Last refreshed: 13 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04564573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing